RSSCategory: Pharmaceuticals

Trial of a novel influenza vaccine commences at NIH

July 1, 2022

A promising influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) is now entering a Phase 1 clinical trial which will see up to 100 healthy adult volunteers inoculated. The vaccine is to be delivered either as a nasal spray or by intramuscular injection. The vaccine candidate known as […]

Continue Reading

Experimental dengue vaccine provides immunity for over four years

June 16, 2022

A dengue vaccine candidate developed by Takeda Pharmaceutical (Takeda), TAK-003, has shown promising results in a Phase 3 trial, providing continued protection against dengue fever through 4.5 years (54 months) post-vaccination. Data revealed TAK-003 prevented 61% of symptomatic dengue cases and 84% of hospitalised cases with no important safety risks identified in a trial known […]

Continue Reading

Complete cancer remission in drug trial development

June 8, 2022

A small clinical trial of the drug dostarlimab in the US has virtually rid each of its 18 participants of colorectal cancer, one of the most dangerous common cancers known to man. Doctors, stunned with the effectiveness of the drug, are now expanding the trial to include gastric, prostate, and pancreatic cancer patients. Dostarlimab (TSR-042) […]

Continue Reading

Dual-action drug treats diabetes and obesity

May 17, 2022

A new type of treatment called the Mounjaro (tirzepatide) shot has just been approved by the US Food and Drug Administration (FDA) for type 2 diabetes. The once-weekly injection for adults was found to be effective at controlling blood sugar levels and – in some cases – obesity. Mounjaro was developed to mimic a hormone […]

Continue Reading

EU drug regulator hopes for approval for adaptive coronavirus vaccines this year

May 10, 2022

The European Medicines Agency (EMA) is hoping to have access to multi-protection vaccines, including one that is able to address several coronavirus variants, by September 2022. Vaccine developers are currently investigating whether shots that target just one variant offer advantages over vaccines that target two variants, said Marco Cavaleri, Head of Biological Health Threats and […]

Continue Reading

Pfizer’s potent antiviral treatment endorsed by WHO

April 22, 2022

The World Health Organization (WHO) has backed the use of Pfizer Inc’s (Pfizer) oral COVID-19 antiviral treatment, Paxlovid, in high-risk patients in the early stages of the disease, to avoid hospitalisation. However, WHO is quick to mention that existing COVID-19 treatments including intravenous and antibody treatments, are not to replace vaccination. The recommendation by WHO […]

Continue Reading

Fourth COVID-19 vaccine dose authorised for Americans over 50

March 31, 2022

The Head of the US Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research, Peter Marks, has encouraged getting a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine for increased protection for high-risk persons. The FDA has already approved a second booster shot or fourth mRNA vaccine dose for American […]

Continue Reading

Pfizer, UNICEF to supply Paxlovid COVID-19 oral treatment for low-, middle-income countries

March 23, 2022

Pfizer Inc. (Pfizer) has announced an agreement with UNICEF to supply nearly 4 million treatment courses of its COVID-19 oral treatment to 95 low- and middle-income countries. The COVID-19 oral treatment, Paxlovid (nirmatrelvir tablets and ritonavir tablets), will be given to all low-income and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa. Countries that […]

Continue Reading

Experimental mRNA-based HIV vaccines enter human trials

March 18, 2022

Biotechnology company Moderna Inc. (Moderna) has commenced a Phase 1 human trial testing three different mRNA vaccines that targets HIV (human immunodeficiency virus). The success of the “safe and highly effective” COVID-19 vaccines enabled this opportunity, run in association with The National Institute of Allergy and Infectious Diseases, US. The idea this time is similar: […]

Continue Reading

Neuroscientists identify new drug target to reduce anxiety

March 16, 2022

A team from the University of Bristol’s School of Physiology, Pharmacology and Neuroscience, UK, have discovered a key pathway in the brain which leads to anxious and fearful behaviour such as “freezing.” Anxiety and certain psychological disorders, which affect an estimated 264-million people worldwide, are survival responses elicited by the periaqueductal grey (PAG) region of […]

Continue Reading